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Objective: Anemia is a common comorbid condition in various inflammatory states and an established predictor of
mortality in patients with chronic heart failure, ischemic heart disease, and end-stage renal disease. The present study of
patients with abdominal aortic aneurysm (AAA) undergoing endovascular repair (EVAR) assessed the relationships
between baseline hemoglobin concentration and AAA size, as well as anemia and long-term survival.
Methods: Between March 1994 and November 2006, 711 patients (65 women, mean age 75.8  7.8 years) underwent
elective EVAR. Anemia was defined as a hemoglobin level<13 g/dL in men and<12 g/dL in women. Post-EVARmean
follow-up was 48.3  32.0 months. Association of hemoglobin level with AAA size was assessed with multiple linear
regression. Mortality was determined with use of the internet-based Social Security Death Index and the electronic
hospital record. Kaplan-Meier survival curves of anemic and nonanemic patient groups were compared by the log-rank
method. Multivariable logistic regression models were used to determine the influence of anemia on vital status after
EVAR.
Results: A total of 218/711 (30.7%) of AAA patients undergoing EVAR had anemia at baseline. After adjustment for
various risk factors, hemoglobin level was inversely related to maximum AAA diameter (:  .144, 95%-CI: 1.482 
.322, P  .002). Post-EVAR survival was 65.5% at 5 years and 44.4% at 10 years. In long-term follow-up, survival was
significantly lower in patients with anemia as compared to patients without anemia (P < .0001 by log-rank). Baseline
hemoglobin levels were independently related to long-term mortality in multivariable Cox regression analysis adjusted
for various risk factors (adjustedHR: 0.866, 95%CI: .783 to .958, P .005).Within this model, statin use (adjustedHR:
.517, 95% CI: .308 to .868, P  .013) was independently related to long-term survival, whereas baseline AAA diameter
(adjusted HR: 1.022, 95% CI: 1.009 to 1.036, P  .001) was an independently associated with increased mortality.
Conclusions: Baseline hemoglobin concentration is independently associated with AAA size and reduced long-term
survival following EVAR. Thus, the presence or absence of anemia offers a potential refinement of existing risk
stratification instruments. ( J Vasc Surg 2007;46:676-81.)Abdominal aortic aneurysm (AAA) is a potentially fatal
condition as its propensity to rupture increases as maximum
AAA diameter increases.1 Aneurysm formation and pro-
gression is associated with chronic transmural aortic wall
inflammation.2,3
Endovascular AAA repair (EVAR), a minimally-invasive
treatment option, has proven advantages over open surgical
AAA repair in the perioperative period.4,5 Protection from
AAA-related death, a crucial end-point after EVAR,6 has been
shown to be as high as in 96% at 5 years and 93% at 9
years.7-9 However, the cumulative 5-year survival of 49%
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676highlights the increased mid-term mortality risk of these
often medically frail patients.7,8
Besides the devastating consequences of AAA rupture,
the systemic implications of aneurysmal disease have re-
cently increasingly been acknowledged.7,8,10-13 In particu-
lar, AAA patients were shown to be at significant risk for
cardiovascular complications5,7,8,14,15 and AAA is now
considered a coronary heart disease risk equivalent.16 Fur-
thermore, AAA size is independently associated with in-
flammatory markers10-13 as well as with an increased risk of
perioperative complications17 and cardiovascular mid-term
mortality after open surgical18 and endovascular19,20 AAA
repair.
Anemia is an important predictor of mortality in
hemodialysis patients and in those with chronic heart
failure and ischemic heart disease.21-26 Anemia of
chronic disease (ACD) is second most prevalent after
anemia of iron deficiency.23,27-29 The prevalence of
ACD increases with age.23,27-29 ACD is typically normo-
chromic, normocytic, and hypoproliferative, and it is
particularly encountered in the setting of chronic inflam-
matory conditions.21,23,27,29 Thus, the pathophysiology
of both AAA and ACD has recently been linked to
chronic inflammation.10,11,13,21,23,29,30
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tionship between hemoglobin concentration and AAA size
and between baseline anemia and long-term survival after
EVAR.
PATIENTS AND METHODS
Between March 1994 and November 2006, 711 con-
secutive patients underwent elective EVAR for infrarenal
AAA at a single center and were entered in a prospectively
maintained database. EVAR was carried out by a dedicated
interdisciplinary team consisting of interventional radiolo-
gists, vascular surgeons, and anesthesiologists as described
previously.31,32
Definitions. Anemia was defined according to the
World Health Organization as a hemoglobin level
Table I. Demographics, risk factors, comorbidities, and ca
undergoing elective endovascular abdominal aortic aneury
Baseline factor No
Female gender, n (%)
Age, mean  SD (years)
Maximum AAA diameter mean  SD (mm)
Height, mean  SD (inches)
Weight, mean  SD (pound) 1
Baseline hemoglobin, mean  SD (g/dl)
Baseline hematocrit, mean  SD (%)
Postprocedural hemoglobin, mean  SD (g/dl)
Postprocedural hematocrit, mean  SD (%)
White blood cell count, mean  SD (cells/mcl)
Creatinine clearance, mean  SD (ml/min)
History of cancer, n (%)
Arterial hypertension, n (%)
Hyperlipidemia, n (%)
Diabetes mellitus, n (%)
Smoking, n (%)
COPD, n (%)
History of cerebrovascular disease, n (%)
History of PAOD, n (%)
History of coronary artery disease, n (%)
History of atrial fibrillation, n (%)
Cardiac risk, n (%)
0
1
2
3
Renal risk, n (%)
0
1
2
3
Pulmonary risk, n (%)
0
1
2
3
Betablocker, n (%)
Statin, n (%)
Antiplatelet therapy, n (%)
ACE inhibitor, n (%)
COPD, Chronic obstructive pulmonary disease; PAOD, Peripheral arterial
*from Fisher exact test.
†from Student t-test.13 g/dL in men and 12 g/dL in women.33 Generaldefinitions34 as well as classification of cardiovascular risk
factors35 followed the standards proposed by the Society
of Vascular Surgery/International Society for Cardiovas-
cular Surgery (SVS/ISCVS).
Patient treatment. A total of 326/711 (45.9%) pa-
tients were treated within five multicenter clinical trials of
specific endografts. The results of several of these trials have
recently been published.36-39 The study protocols were in
accordance with the Declaration of Helsinki and approved
by the local ethics committee. Each patient gave written
informed consent prior to participating in the trial. Further-
more, 385/711 (54.1%) patients were treated with use of
commercially available endografts. Ethics committee ap-
proval was not obtained for these patients, since they were
treated on a regular clinical basis using FDA-approved
vascular medications of 711 consecutive patients
pair
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for EVAR if they had an infrarenal aortic aneurysm that was
50 mm or larger in maximum transverse diameter or if they
had documented imaging evidence of 1.5 times the refer-
ence aortic diameter and expansion rate 10% per year.
Exclusion criteria for the present investigation were a life
expectancy of 1 year, pregnancy, systemic infection, in-
flammatory aneurysm, AAA associated with connective tis-
sue disease, or Marfan’s syndrome and an untreatable
bleeding diathesis or hypercoagulable state.
All patient baseline characteristics and laboratory data
were collected preoperatively and are described in Table I.
Follow-up. Mean follow-up was 48.3 32.0months.
The Social Security Death Index (SSDI, http://ssdi.
rootsweb.com/) was used to ascertain mortality as of No-
vember 30, 2006.
Statistical analysis. Continuous data are presented as
mean standard deviation (SD). Categorical data are given
as absolute numbers and percentages. For univariable com-
parison of unpaired continuous data, the Student t test was
used. For univariable comparison of paired continuous
data, the paired t test was utilized. Categorical data was
compared with use of the Fisher exact test. Multiple linear
regression (adjusted for all baseline variables with signifi-
cant difference in univariable comparison and for factors
with potential impact on baseline AAA size and cause of
anemia) was performed to assess the association between
hemoglobin concentration and AAA size. Survival rates
according to presence or absence of anemia at baseline are
presented as Kaplan-Meier curves and compared by means
of the log-rank test. Multivariable Cox proportional haz-
ards analysis (adjusted for all baseline variables with signif-
icant difference in univariable comparison and for factors
with potential impact and cause of anemia23 as well as for
factors with impact on decreased patient survival) was ap-
plied to assess the effect of hemoglobin concentration on
survival. Results of the Cox regression model were pre-
sented as the hazard ratio (HR) and the 95% confidence
interval (95% CI).
A P value .05 was considered statistically significant.
All calculations were performed using SPSS (Version 13.0,
SPSS, Chicago, Ill).
RESULTS
Anemia was present in 218/711 (30.7%) of patients
undergoing EVAR. Table I outlines patient demographic
data, risk factors, comorbidities, and cardiovascular medi-
cations of patients contained in the present study. Patients
with anemia were significantly older, had a larger maximum
AAA diameter, as well as a lower body weight and
creatinine clearance compared to patients without anemia.
Hyperlipidemia was less prevalent, whereas history of symp-
tomatic atherothrombosis as well as betablocker and anti-
platelet therapy was more frequent in patients with anemia
compared with patients without anemia. Furthermore, pa-
tients with anemia were less likely to have favorable cardiac,
renal, and pulmonary risk scores than were patients without
anemia.Postprocedural hemoglobin concentration and hemat-
ocrit were significantly lower in patients diagnosed with
anemia at baseline as compared to patients without anemia
(P .0001 and P .001, Table I). Postprocedural hemo-
globin concentrations as well as hematocrit were signifi-
cantly lower compared with preprocedural values in both
patients with and without anemia at baseline (P  .0001).
With use of cell savers, transfusion was necessary in a total of
48/711 (6.8%) patients: 15/493 (3%) of patients without
anemia at baseline and 30/218 (14%) of patients with
anemia at baseline received blood products (P  .0001).
Hemoglobin level was inversely related to maximum
AAA diameter (: .144, 95% CI: 1.482 to .322, P 
.002) within a linear regression model adjusted for age;
weight; height; creatinine clearance; hyperlipidemia; diabe-
tes mellitus; smoking; antiplatelet and beta blocker use;
cerebrovascular disease; PAOD; coronary artery disease;
cardiac, pulmonary and renal risk score. Conversely, maxi-
mum AAA diameter was inversely related to hemoglobin
concentration (  .172, 95% CI: 1.947 to .214,
P  .015) in this model.
Post-EVAR 30-day rates of surgical conversion, AAA
rupture, and death did not differ between both groups (P
.05, Table II). Survival was 65.5% after 5 years and 44.4%
after 10 years (Fig 1). Long-term survival was significantly
lower in patients with anemia as compared to patients
without anemia (P  .0001, Fig 1).
Multivariable Cox proportional hazards analysis ad-
justed for age; maximum AAA diameter; weight; creatinine
clearance; history of cancer; hyperlipidemia; diabetes mel-
litus; smoking; COPD; cerebrovascular disease; PAOD;
coronary artery disease; cardiac, pulmonary and renal risk
score; beta blocker, statin, antiplatelet, and ACE inhibitor
use confirmed baseline hemoglobin levels to be indepen-
dently associated with long-term mortality post-EVAR
(adjusted HR: .866, 95% CI: .783 to .958, P  .005;
Table III). Additionally, patient age (adjusted HR: 1.040,
95% CI: 1.015 to 1.065, P  .002), maximum AAA
diameter (adjusted HR: 1.022, 95% CI: 1.009 to 1.036,
P .001), diabetes mellitus (adjusted HR: 1.819, 95% CI:
1.216 to 2.720, P  .004) as well as pulmonary (adjusted
HR: 1.398, 95% CI: 1.157 to 1.689, P  .001) and renal
Table II. Thirty-day outcomes of 711 consecutive
patients undergoing elective endovascular abdominal
aortic aneurysm repair
30-day outcomes
All patients
n  711
No anemia
n  493
Anemia
n  218 P*
Procedural
conversion 7 (0.09%) 5 (1.0%) 2 (0.09%) 1.0000
Procedural death 0 (0.0%) 0 (0%) 0 (0%) N/A
Procedural rupture 0 (0%) 0 (0%) 0 (0%) N/A
30-day conversion 10 (1.4%) 8 (1.6%) 2 (0.09%) .7316
30-day death 10 (1.4%) 6 (1.2%) 4 (1.8%) N/A
30-day rupture 0 (0%) 0 (0%) 0 (%) N/A
*from Fisher exact test.risk score (adjusted HR: 1.595, 95% CI: 1.234 to 2.062,
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survival, whereas statin use was associated with greater
survival (adjusted HR: .517, 95% CI: .308 to .868, P 
.013) in this model (Table III).
DISCUSSION
Mediation by elevated pro-inflammatory cytokines is
common to the pathophysiology of both AAA and
ACD.40-42 In the present study, decreased hemoglobin
concentration, as a marker of chronic disease, was shown to
be independently associated with AAA size and reduced
long-term survival after EVAR.
In the present series, 30-day mortality after EVAR
was 1.4%, whereas 5-year and 10-year survival were
65.5% and 44.4%, respectively. As more long-term fol-
low-up data on patients undergoing treatment for AAA
becomes available,7,8 the systemic implications of ab-
dominal aortic aneurysmal disease are becoming more
apparent. Still, long-term survival of AAA patients com-
pares well with patients with symptomatic cerebrovascu-
lar disease43,44 and various types of malignancies such as
colon cancer45 and is substantially higher as compared to
patients with intermittent claudication.46 Considering
the fact that AAA patients are at significant risk for
cardiovascular complications,7,8,17,18,20 AAA is now
considered a CHD risk equivalent.16
Maximum AAA diameter as a potential marker of sys-
temic inflammatory burden has been shown to directly
correlate with inflammatory markers such as interleukin-6
and C-reactive protein.10-13 Furthermore, maximum AAA
diameter as an expression of AAA size was shown to influ-
ence on rates of perioperative cardiovascular complica-
tions,17 and cardiovascular midterm mortality after open
surgical AAA repair18 and after EVAR.7,8,20 The present
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Fig 1. Cumulative survival of patients with and without anemia
undergoing elective endovascular abdominal aortic aneurysm re-
pair (P  .0001 by log-rank).study confirms the highly significant inverse relationshipbetween AAA size and long-term survival, underlining
previous observations regarding mid-term survival after
EVAR.7,8,20
Anemia has traditionally been viewed as an “innocent
bystander” and accepted as an abnormality associated with
chronic diseases.22 However, the presence of anemia has
recently been identified as an important predictor of in-
creased mortality in patients with end-stage renal disease,
chronic heart failure and ischemic heart disease.21-26 In
inflammatory states, increased hepcidin concentrations
cause iron sequestration in macrophages, resulting in
hypoferremia and anemia.21,23,29,47 Furthermore, pro-
inflammatory cytokines induce hypoferremia by modulat-
ing macrophage iron metabolism via induction of ferritin
biosynthesis.48 In the present series, anemia was highly
prevalent and was independently associated with AAA size
and increased mortality during long-term follow-up after
multivariable adjustment of a multitude of clinical baseline
factors. Given these associations, we speculate that there
may be a role for anemia as an inflammatory surrogate
marker and risk stratification tool in patients with AAA,
although no direct link between anemia and inflammatory
markers was established in the present study.
Although the effect of statins in reducing the risk of
cardiovascular disease is well established, robust data on its
dedicated use in patients with AAA is scarce. Statins are
associated with greater long-term survival after open AAA
surgery49 and after EVAR.50 Besides their well-studied
lipid-lowering and anti-inflammatory properties associated
with improved cardiovascular outcomes, statins reduce lev-
els of enzymes involved in aortic wall degeneration in cell
culture51,52 and in human AAA tissue.53 The present series
confirms statin use to be an independent predictor of
decreased long-term mortality in AAA patients, thereby
underlining important observations from the EUROSTAR
registry.50 Fewer than 50% of patients in the present series
were prescribed statins prior to EVAR. The fact that treat-
ment of cardiovascular risk is currently still suboptimal in
patients with AAA has recently been highlighted by oth-
ers.15 Despite the fact that AAA has been recognized as a
coronary heart disease risk equivalent,16 dedicated recom-
mendations regarding drug treatment are currently lacking.
Three shortcomings of the present study must be ad-
dressed. First, since ACD can nowadays not be diagnosed
even with specific laboratory tests directly aimed at differ-
entiating anemia of inflammation from anemia resulting
from other causes,23,54 we cannot entirely rule out that
causes for anemia other than chronic inflammation might
have contributed to the above-described results. Neverthe-
less, three features of our analysis render the impacts of such
artefacts less likely. By including age, creatinine clearance,
and history of cancer in the multivariable analysis assessing
factors contributing to reduced survival, the impact of these
major causes of anemia was minimized.23 Furthermore, the
inverse relationship of hemoglobin levels and AAA size
observed in this study further support assumptions for a
link between anemia and chronic inflammation in this
series. Second, the lack of available data to enable system-
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patients who underwent elective EVAR prevented an as-
sessment of the direct relationship between anemia and
cardiovascular events. Third, since anemia was diagnosed
by a blood test prior to EVAR, the impact of anemia
occurring during follow-up cannot be assessed utilizing this
approach.
In summary, in the present series baseline hemoglobin
concentration, as a marker of chronic disease, was shown to
be independently associated with both AAA size and re-
duced long-term survival following EVAR. Thus, the pres-
ence or absence of anemia offers a potential refinement of
existing risk stratification instruments. Since no direct link
between inflammatory markers and anemia could be estab-
lished in the present series, further investigations into the
molecular linkage between anemia, inflammatory changes
and AAA are warranted.
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